Mitoxantrone is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. An anthracenedione-derived antineoplastic agent.
- Mechanism
- Curator reviewed
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.
- Primary indication
- For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosisCurator reviewed · 15 structured indications
- Formula / weight
- C22H28N4O6 · 444.4809 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1987
- Also known as
- Mitoxantrone Liposome
- Code names
- CL 232315
Resolves to
KKZJGLLVHKMTCM-UHFFFAOYSA-NSMILESOCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Mitoxantrone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account